Zacks Investment Research | Jun 18, 2017 09:43PM ET
Medtronic plc’s (NYSE:MDT) strategic progress within its core Cardiac Rhythm & Heart Failure business majorly continues banking on its wide and growing Atrial Fibrillation (AF) solution sub segment.
Following the FDA approval of the company’s Visia AF ICD (implantable cardioverter defibrillator), Medtronic once again has come up with a favorable study result on Reactive ATP (atrial-based antitachycardia pacing) therapy.
Per announcement, based on the analysis of a real-world 8,800 patient population, Medtronic’s Reactive ATP therapy slows the progression of AF in patients who are being implanted with cardiac devices. This study was presented at the EHRA EUROPACE-CARDIOSTIM 2017 as a late breaking clinical trial.
Medtronic claims Reactive ATP as a painless pacing therapy, solely found on the company’s pacemakers, implantable cardioverter defibrillators (ICDs) and cardiac resynchronization therapy (CRT) devices.
This procedure keeps sending pacing pulses to the atria during abnormally fast rhythms or heartbeats, thereby helping to restore the heart’s normal rhythm and slowing the progression of AF.
Market Prospects
Notably, per the American Heart Association (AHA), Atrial Fibrillation is an irregular heartbeat (arrhythmia) which may lead to blood clots, stroke, heart failure and other heart-related complications.
This disease has become a threat to the entire world at present as researches reveal about its pandemic spread at an alarming rate. According to information provided by AHA,at least 2.7 million Americans are living with AF. While globally, AF affects more than 33 million people.
While this disease constantly imposes a significant burden on the entire healthcare community, the global AF solutions market grows in leaps and bounds. Per the RnR Market Research, this industry is projected to exhibit a CAGR of over 13.3% during 2016-2021.
Medtronic’s consistent efforts to reap benefits out of this is completely strategic. Its AF solutions business, in the last reported fourth-quarter 2017 grew in the mid-30s (percentage more than twice the market growth). This strong quarter was based on its aortic plan advanced following the FIRE AND ICE trial, which was published in the New England Journal of Medicine.
We expect the latest development to add further impetus to the company’s growth trajectory in this niche.
Price Performance
In the last one month, Medtronic has underperformed the Zacks categorized Medical Product industry. Per the last share price movement, the stock has added 4.8% compared with the 5% gain of the broader industry.
Zacks Rank & Key Picks
Medtronic currently carries a Zacks Rank #3 (Hold). Some better-ranked medical stocks are Align Technology, Inc. (NASDAQ:ALGN) , Inogen, Inc. (NASDAQ:INGN) and Accelerate Diagnostics, Inc. (NASDAQ:AXDX) . Both Align Technology and Inogen sport a Zacks Rank #1 (Strong Buy), while Accelerate Diagnostics carries a Zacks Rank #2 (Buy). You can see Zacks Investment Research
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.